RxDoctor Payments Data

Padmashree Velury, MD

Geriatric Medicine · Lawton, OKNPI 1639249139

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AstraZeneca at 24.6% of the total. Reporting peaked in 2019 at $505 and has fallen 92.6% since, to $37 in 2025.

$1,412in general payments, 2019–2025

Across 99 payments — averaging $14.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$347
  • Boehringer Ingelheim$331
  • Merck$208
  • Lilly USA, LLC$107
  • Pfizer$68
  • Amgen$56
  • plus $296 from 9 others

What the payments were for

  • Food & beverage$1,406100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,412 in reported general payments places this provider in the 80th percentile of 25 geriatric medicine providers in Oklahoma.

See all geriatric medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$206,832
Medicare patients
339
Services billed
2,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$65,209
JardianceEmpagliflozin51$47,692
JanuviaSitagliptin Phosphate40$46,226
OzempicSemaglutide29$34,263
TrulicityDulaglutide20$28,157
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$21,651
EntrestoSacubitril/Valsartan12$15,312
Repatha SureclickEvolocumab19$14,859
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$7,425
Janumet XrSitagliptin Phos/Metformin Hcl11$7,328
Metoprolol Succinate196$3,670
Rosuvastatin Calcium226$3,116
Sucralfate12$3,030
Levothyroxine Sodium396$3,010
Atorvastatin Calcium269$2,429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$65,20958 claims
MerckJanuvia, Janumet Xr$208$53,55451 claims
Boehringer IngelheimJardiance$331$47,69251 claims
Novo NordiskOzempic$53$34,26329 claims
Lilly USA, LLCTrulicity$107$28,15720 claims
GSKTrelegy Ellipta$49$21,65121 claims
NovartisEntresto$22$15,31212 claims
AbbVieSynthroid$16$1,45317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 25 geriatric medicine providers in Oklahoma.

Other geriatric medicine in Lawton

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →